Anti-SRP immune-mediated necrotizing myopathy: A critical review of current concepts

Front Immunol. 2022 Oct 13:13:1019972. doi: 10.3389/fimmu.2022.1019972. eCollection 2022.

Abstract

Purpose of review: This review aims to describe clinical and histological features, treatment, and prognosis in patients with anti-signal recognition particle (SRP) autoantibodies positive immune-mediated necrotizing myopathy (SRP-IMNM) based on previous findings.

Previous findings: Anti-SRP autoantibodies are specific in IMNM. Humoral autoimmune and inflammatory responses are the main autoimmune characteristics of SRP-IMNM. SRP-IMNM is clinically characterized by acute or subacute, moderately severe, symmetrical proximal weakness. Younger patients with SRP-IMNM tend to have more severe clinical symptoms. Patients with SRP-IMNM may be vulnerable to cardiac involvement, which ought to be regularly monitored and cardiac magnetic resonance imaging is the recommended detection method. The pathological features of SRP-IMNM are patchy or diffuse myonecrosis and myoregeneration accompanied by a paucity of inflammatory infiltrates. Endoplasmic reticulum stress-induced autophagy pathway and necroptosis are activated in skeletal muscle of SRP-IMNM. Treatment of refractory SRP-IMNM encounters resistance and warrants further investigation.

Summary: Anti-SRP autoantibodies define a unique population of IMNM patients. The immune and non-immune pathophysiological mechanisms are involved in SRP-IMNM.

Keywords: ER stress; anti-SRP autoantibodies; cardiac involvement; immune-mediated necrotizing myopathy; refractory.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Autoantibodies
  • Autoimmune Diseases*
  • Humans
  • Muscular Diseases* / therapy
  • Myositis*
  • Necrosis
  • Signal Recognition Particle

Substances

  • Signal Recognition Particle
  • Autoantibodies